Cameco (CCJ) Q2 2026 Earnings Call Transcript

Cameco maintained its 2026 uranium outlook (share of production 19.5–21.5 million lb U3O8) despite temporary Northern Saskatchewan disruptions, while reporting stronger long-term uranium contracting with realized-price improvement tied to a firmer market and FX. On the nuclear build side, Westinghouse disclosed a conditional DOE commitment of $17.5B to support AP1000 long-lead items and a twin-pack project spend of $20B–$26B (Westinghouse share 40%–45%) with average project EBITDA margins around 20%. The company also confidentially submitted a draft Westinghouse Form S-1 for a proposed IPO, with the uranium market described as constructive as long-term prices reach decade highs and floor/ceiling contract levels rise (high-70s floors to ~160 ceilings).

Analysis

The incremental signal is not just that uranium is tight; it is that buyers are increasingly willing to pay up for de-risked supply and de-risked execution. That favors CCJ over higher-beta uranium names because its edge is contract visibility, operating credibility, and exposure to the parts of the cycle that rerate first: term pricing, fuel services, and long-lead reactor work. The second-order loser is the long tail of unproven developers and new conversion/enrichment entrants whose economics depend on utilities believing future supply promises; if buyers stay skeptical, capital stays expensive and timeline slippage widens the gap versus incumbent supply.

Near term, the main catalyst path is not production growth but a sequence of contracting and project-finance milestones over the next 1-3 months. Any confirmation that long-lead item financing is translating into definitive utility agreements should tighten the market’s view of future uranium demand, while a Westinghouse listing could surface sum-of-the-parts value and reduce the conglomerate discount on CCJ/BEP exposure. The risk is that investors extrapolate reactor headlines into immediate earnings; the actual earnings bridge is slower, with meaningful cash-flow leverage arriving first through backlog, then through recurring fuel/services, and only later through delivered builds.

Contrarian view: the market may be underestimating how much scarcity premium can persist even if headline supply additions are announced, because utilities care about proven track record rather than announced megawatts. Conversely, the move could be overdone if the Street prices in too much near-term monetization from the reactor pipeline before FIDs, financing, and supply-chain sequencing are locked. The falsifier is simple: if 2026 output guidance slips again or if definitive agreement milestones stall into year-end, the stock should de-rate back toward a pure commodity multiple rather than an execution premium.

Key Decisions for Investors

• Go long CCJ on any post-call weakness and hold for 1-3 months into contracting and DOE/DOC milestone headlines; target a rerating toward a higher-quality uranium compounder multiple rather than a spot-price beta trade. Falsify if guidance is cut again or if long-term contracting cadence slows materially.
• Buy CCJ 6-12 month call spreads instead of outright stock to express the sum-of-the-parts and contracting-cycle upside while capping premium burn if Westinghouse milestones slip. Best entry is on a pullback after the market digests the event.
• Pair trade: long CCJ / short UUUU for 3-6 months. Thesis is that utilities pay up for scale, reliability, and contracted visibility first; UUUU is more exposed to financing/friction risk and less to the premium valuation attached to proven operating assets. Cover if uranium prices move sharply higher on a broad spot squeeze.
• Watchlist rather than trade: BEPC/BEP into any credible Westinghouse IPO timetable. A clean filing or valuation disclosure could surface embedded Brookfield value, but absent definitive steps this is optionality, not an earnings catalyst.
• If you want cleaner risk control, buy CCJ only after a confirmed definitive agreement or FID-related announcement; the market may be front-running a 6-18 month story with limited near-term cash-flow impact. This is the best risk/reward entry if the stock spikes on narrative before the paperwork lands.